OBJECTIVES: Assess the efficacy of a single infusion of a high titer pertussis immune globulin for the treatment of severe pertussis in children.

Condition	Treatment or Intervention	Phase
Pertussis Whooping Cough	Drug: immune globulin	Phase III

Further Study Details: 

Expected Total Enrollment:  174

PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are randomized to receive an infusion of either pertussis immune globulin or placebo (0.9% saline). Patients are followed every 2 weeks for up to 6 months.

Ages Eligible for Study:  up to  5 Years,  Genders Eligible for Study:  Both

Criteria

• Documented infection with Bordetella pertussis

Study chairs or principal investigators

Scott A. Halperin,  Study Chair,  IWK Grace Health Centre   

Study ID Numbers:  199/13322; IWK-FDR001044; P9701
Record last reviewed:  June 2000
Last Updated:  October 13, 2004
Record first received:  October 18, 1999
ClinicalTrials.gov Identifier:  NCT00004422
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08